593 related articles for article (PubMed ID: 26906526)
21. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.
Garcia JM; Friend J; Allen S
Support Care Cancer; 2013 Jan; 21(1):129-37. PubMed ID: 22699302
[TBL] [Abstract][Full Text] [Related]
22. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia.
Hamauchi S; Furuse J; Takano T; Munemoto Y; Furuya K; Baba H; Takeuchi M; Choda Y; Higashiguchi T; Naito T; Muro K; Takayama K; Oyama S; Takiguchi T; Komura N; Tamura K
Cancer; 2019 Dec; 125(23):4294-4302. PubMed ID: 31415709
[TBL] [Abstract][Full Text] [Related]
23. Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial).
Sousa MS; Martin P; Johnson MJ; Lind M; Maddocks M; Bullock A; Agar M; Chang S; Kochovska S; Kinchin I; Morgan D; Fazekas B; Razmovski-Naumovski V; Lee JT; Itchins M; Bray V; Currow DC
PLoS One; 2023; 18(5):e0285850. PubMed ID: 37195996
[TBL] [Abstract][Full Text] [Related]
24. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study.
Takayama K; Takiguchi T; Komura N; Naito T
Cancer Med; 2023 Feb; 12(3):2918-2928. PubMed ID: 36394148
[TBL] [Abstract][Full Text] [Related]
26. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model.
Northrup R; Kuroda K; Duus EM; Barnes SR; Cheatham L; Wiley T; Pietra C
Support Care Cancer; 2013 Sep; 21(9):2409-15. PubMed ID: 23579947
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
28. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
29. Oncology Update: Anamorelin.
Prommer E
Palliat Care; 2017; 10():1178224217726336. PubMed ID: 28855797
[TBL] [Abstract][Full Text] [Related]
30. Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan.
Takayama K; Kojima A; Honda C; Nakayama M; Kanemata S; Endo T; Muro K
Cancer Med; 2024 May; 13(9):e7170. PubMed ID: 38693813
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of Anamorelin for the Treatment of Cancer Cachexia and Factors Associated with Weight Gain].
Okuda Y; Saitoh T; Mikame Y; Shinada M; Fujimura S; Suga R; Kobayashi N; Nakata M; Arai D; Nakazawa T; Yamaguchi H; Imai Y
Gan To Kagaku Ryoho; 2024 May; 51(5):529-533. PubMed ID: 38881063
[TBL] [Abstract][Full Text] [Related]
32. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
Dobs AS; Boccia RV; Croot CC; Gabrail NY; Dalton JT; Hancock ML; Johnston MA; Steiner MS
Lancet Oncol; 2013 Apr; 14(4):335-45. PubMed ID: 23499390
[TBL] [Abstract][Full Text] [Related]
33. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis.
Taniguchi J; Mikura S; da Silva Lopes K
Sci Rep; 2023 Sep; 13(1):15257. PubMed ID: 37709824
[TBL] [Abstract][Full Text] [Related]
35. Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study.
Iwai N; Sakai H; Oka K; Sakagami J; Okuda T; Hattori C; Taniguchi M; Hara T; Tsuji T; Komaki T; Kagawa K; Doi T; Ishikawa T; Yasuda H; Itoh Y
Support Care Cancer; 2023 Jan; 31(2):115. PubMed ID: 36640181
[TBL] [Abstract][Full Text] [Related]
36. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia.
Takeda T; Sasaki T; Okamoto T; Ishitsuka T; Yamada M; Nakagawa H; Mie T; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Intern Med; 2023 Jul; 62(13):1887-1893. PubMed ID: 36418096
[TBL] [Abstract][Full Text] [Related]
37. Anamorelin in Japanese patients with cancer cachexia: an update.
Wakabayashi H; Arai H; Inui A
Curr Opin Support Palliat Care; 2023 Sep; 17(3):162-167. PubMed ID: 37389636
[TBL] [Abstract][Full Text] [Related]
38. Prokinetics and ghrelin for the management of cancer cachexia syndrome.
Malik JS; Yennurajalingam S
Ann Palliat Med; 2019 Jan; 8(1):80-85. PubMed ID: 30525771
[TBL] [Abstract][Full Text] [Related]
39. The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials.
Rezaei S; de Oliveira LC; Ghanavati M; Shadnoush M; Akbari ME; Akbari A; Hadizadeh M; Ardehali SH; Wakabayashi H; Elhelali A; Rahmani J
J Oncol Pharm Pract; 2023 Oct; 29(7):1725-1735. PubMed ID: 37525932
[TBL] [Abstract][Full Text] [Related]
40. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM; Shepherd FA; Millward M; Perrone F; Seymour L; Liu G; Sun S; Cho BC; Morabito A; Leighl NB; Stockler MR; Lee CW; Wierzbicki R; Cohen V; Blais N; Sangha RS; Favaretto AG; Kang JH; Tsao MS; Wilson CF; Goldberg Z; Ding K; Goss GD; Bradbury PA; ; ;
Lancet Oncol; 2014 Nov; 15(12):1379-88. PubMed ID: 25439692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]